Therefore, sotorasib is being studied in combination with MEK inhibitors or anti-PD-1 agents in NSCLC and CRC in CodeBreak101 [90], while Kristal-7 will provide data about adagrasib and pembrolizumab doublet in NSCLC. This evidence concerns the gene MAP2K7 and colorectal carcinoma.